Bharat Biotech reveals positive data from animal trial of Covaxin
Category: #health  By Saipriya Iyer  Date: 2020-09-15
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Bharat Biotech reveals positive data from animal trial of Covaxin

Bharat Biotech, an Indian biotechnology company, has reportedly revealed positive results from the animal trial of Covaxin, India’s COVID-19 vaccine candidate.

In the animal trial phase, 20 monkeys in the country were studied, being administered two doses of the Covaxin BBV 152, an inactivated SARS-CoV-2 vaccine. These monkeys were administered with 2 doses of the vaccine in a 14-day span, where the results showed strong immune responses and a significant reduction in virus replication in the throat, nasal cavity, and lung tissues. Bharat Biotech has reportedly stated that the trial data also has demonstrated the protective efficacy of the vaccine in a live viral challenge model, increasing SARS-CoV-2 specific IgG & neutralizing antibodies.

The selected monkeys were divided into 4 groups, out of which, 3 groups were administered the vaccination while the remaining group was administered with placebo. According to the results, the 3 vaccinated groups showed no signs of pneumonia, while the placebo group had evidences of pneumonia.

Sources familiar with the matter also have stated that Covaxin has significantly developed a robust immune response, thereby preventing the disease among primates upon high exposure to the virus.

In the Phase I/II clinical study, Bharat Biotech and ICMR (Indian Council of Medical Research) have conducted the vaccine trial among 1,125 subjects at 12 institutes in India, including PGIMS in Rohtak, Nizam’s Institute of Medical Sciences in Hyderabad, King George Hospital in Visakhapatnam, and AIIMS (All India Institute of Medical Sciences) in New Delhi & Patna. Additionally, in the Phase I trial conducted in India, the vaccine candidate demonstrated immunogenicity and high efficacy among non-human primates. There have also been no side-effects of Covaxin observed in the animal trials.

PGI (Post Graduate Institute) Rohtak has previously stated that it will commence the Phase II human trial of Bharat Biotech’s Covaxin.

Source credit:

https://english.jagran.com/india/indias-coronavirus-vaccine-candidate-covaxin-shows-encouraging-results-in-animal-trial-10016670



About Author

Saipriya Iyer

Email: [email protected]   linkdin twitter

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

More News By Saipriya Iyer

 Tabletop Tape Dispensers  market valuation to surge at healthy CAGR through 2026

Tabletop Tape Dispensers market valuation to surge at healthy CAGR through 2026

By Saipriya Iyer

A comprehensive research study on Tabletop Tape Dispensers market added by Market Study Report provides insights into the market size and growth trends of this industry over the forecast timeline. The study evaluates key aspects of Tabletop Tape D...

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

By Saipriya Iyer

MarketStudyReport.com presents latest report on global General Well-Being Dietary Supplements Market, which evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The re...

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

By Saipriya Iyer

The report Eugenia Jambolana Extract market provides high-quality information regarding the major market trends, product types and their application scope, competitive landscape, and impact of COVID-19 outbreak.

.

Request a...